[go: up one dir, main page]

ES2124470T3 - Lectina recombinante de muerdago. - Google Patents

Lectina recombinante de muerdago.

Info

Publication number
ES2124470T3
ES2124470T3 ES95109949T ES95109949T ES2124470T3 ES 2124470 T3 ES2124470 T3 ES 2124470T3 ES 95109949 T ES95109949 T ES 95109949T ES 95109949 T ES95109949 T ES 95109949T ES 2124470 T3 ES2124470 T3 ES 2124470T3
Authority
ES
Spain
Prior art keywords
polypeptides
molecules
contain
nucleic acid
mistletoe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95109949T
Other languages
English (en)
Inventor
Hans Lentzen
Jurgen Eck
Axel Baur
Holger Zinke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madaus Holding GmbH
Original Assignee
Madaus AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madaus AG filed Critical Madaus AG
Application granted granted Critical
Publication of ES2124470T3 publication Critical patent/ES2124470T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION TRATA DE MOLECULAS DE ACIDO NUCLEICO, QUE CODIFICAN PREPROTEINAS, QUE TIENEN DESPUES DE SU MADURACION LA ACTIVIDAD BIOLOGICA DEL DIMERO DE LA LECTINA DEL MUERDAGO, VECTORES, QUE CONTIENEN ESTAS MOLECULAS DE ACIDO NUCLEICO, HOSPEDADORES Y POLIPETIDOS O DIMEROS DE POLIPEPTIDOS TRANSFORMADOS CON ESTOS VECTORES, QUE CODIFICARAN MOLECULAS DE ESTOS ACIDOS NUCLEICOS. LOS POLIPEPTIDOS O DIMEROS DE POLIPEPTIDOS DE LA INVENCION SON DE UTILIDAD MULTIPLE TERAPEUTICA. TAMBIEN TRATA LA INVENCION DE INMUNOTOXINAS Y MEDICAMENTOS, QUE CONTIENEN LOS POLIPEPTIDOS O DIMEROS DE POLIPEPTIDOS DE LA INVENCION. FINALMENTE TRATA LA INVENCION DE COMPOSICIONES DE DIAGNOSTICO, QUE CONTIENEN LAS MOLECULAS DE ACIDO NUCLEICO DE LA INVENCION, LOS POLIPEPTIDOS O DIMEROS DE POLIPEPTIDOS DE LA INVENCION Y/O PRIMER, QUE HIBRIDAN ESPECIFICAMENTE CON LAS MOLECULAS DE ACIDO NUCLEICO DE LA INVENCION.
ES95109949T 1995-06-26 1995-06-26 Lectina recombinante de muerdago. Expired - Lifetime ES2124470T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95109949A EP0751221B1 (de) 1995-06-26 1995-06-26 Rekombinantes Mistellektin (rML)

Publications (1)

Publication Number Publication Date
ES2124470T3 true ES2124470T3 (es) 1999-02-01

Family

ID=8219389

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95109949T Expired - Lifetime ES2124470T3 (es) 1995-06-26 1995-06-26 Lectina recombinante de muerdago.

Country Status (21)

Country Link
US (1) US6271368B1 (es)
EP (3) EP0751221B1 (es)
JP (2) JP3291548B2 (es)
KR (1) KR100292918B1 (es)
CN (1) CN1160457C (es)
AR (1) AR003961A1 (es)
AT (1) ATE170922T1 (es)
AU (1) AU719297B2 (es)
BR (1) BR9609223A (es)
CA (1) CA2225924C (es)
CZ (1) CZ292689B6 (es)
DE (1) DE59503524D1 (es)
DK (1) DK0751221T3 (es)
ES (1) ES2124470T3 (es)
HU (1) HU225738B1 (es)
NO (1) NO327165B1 (es)
PL (1) PL193281B1 (es)
RU (1) RU2241750C2 (es)
SK (1) SK173197A3 (es)
WO (1) WO1997001636A2 (es)
ZA (1) ZA965361B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0751221T3 (da) * 1995-06-26 1999-06-07 Madaus Ag Koeln Rekombinant misteltenlectin
DK1012256T3 (da) * 1997-01-02 2004-07-12 Viscum Ag Rekombinante fusionsproteiner på basis af ribosom-inaktiverende proteiner fra misteltenen Viscum album
CN1104438C (zh) * 1997-06-02 2003-04-02 山东医科大学附属医院 槲寄生提取物及其用途
DE19804210A1 (de) * 1998-02-03 1999-08-12 Biosyn Arzneimittel Gmbh Rekombinante Mistellektine
KR20010011330A (ko) * 1999-07-27 2001-02-15 김종배 한국산 겨우살이 추출물과 이로부터 분리한 단백질 및 상기 단백질에서 분리한 렉틴
DE10044027A1 (de) * 2000-09-06 2002-03-14 Viscum Ag Rekombinant erzeugtes Mistellektin (ML III)
NZ526202A (en) * 2000-11-14 2005-08-26 Ian Pryme Orally ingestible preparation of mistletoe lectins, ML-I, ML-II and ML-III and methods fro treating cancer and autoimmune diseases
DK1418800T3 (da) 2001-07-09 2007-09-24 Univ Copenhagen Metoder og stiklinger til massedyrkning af planteparasitter
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
JP4681226B2 (ja) * 2001-12-21 2011-05-11 ビスカム・アーゲー ヤドリギレクチンに対する個体の応答性を判定する方法
DE102011003478A1 (de) * 2011-02-01 2012-08-02 Cytavis Biopharma Gmbh Antivirales Mittel enthaltend rekombinante Mistellektine
EP2508195A1 (de) * 2011-04-06 2012-10-10 Cytavis BioPharma GmbH Arzneimittel enthaltend rekombinante Mistellektine zur Behandlung des malignen Melanoms
DK2723374T3 (da) 2011-06-27 2017-11-20 Melema Pharma Gmbh Rekombinant mistelten-lektin og dettes anvendelse som adjuvans
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3205348A1 (de) 2016-02-15 2017-08-16 Melema Pharma GmbH Arzneimittel enthaltend rekombinante mistellektine zur behandlung von hirntumoren
CN106166223A (zh) * 2016-09-17 2016-11-30 四川易创生物科技有限公司 一种治疗肺肾阴亏、潮热盗汗的中药组合物及其制备方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN115025207B (zh) * 2022-06-23 2023-02-07 黑龙江中医药大学 一种用于治疗类风湿性关节炎的药物及其制备方法
CN117924453B (zh) * 2024-03-19 2024-08-06 广东现代汉方科技有限公司 一种甘露糖特异性凝集素重组植物蛋白的制备方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127532A (en) * 1989-09-12 2000-10-03 Board Of Trustees Operating Michigan State University Lectin cDNA and transgenic plants derived therefrom
US5407454A (en) * 1989-11-07 1995-04-18 Pioneer Hi-Bred International, Inc. Larvicidal lectins and plant insect resistance based thereon
DE4221836A1 (de) * 1992-07-03 1994-01-05 Gabius Hans Joachim Prof Dr Das biochemisch aufgereinigte Mistel-Lektin (ML-1) als therapeutisch anwendbarer Immunmodulator
DE4341476A1 (de) * 1993-12-02 1995-06-08 Uwe Dr Pfueller Mittel zur Untersuchung und Beeinflussung zellulärer Veränderungen auf Lektinbasis
DK0751221T3 (da) * 1995-06-26 1999-06-07 Madaus Ag Koeln Rekombinant misteltenlectin

Also Published As

Publication number Publication date
RU2241750C2 (ru) 2004-12-10
CN1192240A (zh) 1998-09-02
CA2225924A1 (en) 1997-01-16
CZ292689B6 (cs) 2003-11-12
KR100292918B1 (ko) 2001-06-15
HUP9900316A2 (hu) 1999-05-28
NO976058L (no) 1998-02-03
ATE170922T1 (de) 1998-09-15
JP3291548B2 (ja) 2002-06-10
EP0884388A1 (de) 1998-12-16
NO327165B1 (no) 2009-05-04
ZA965361B (en) 1997-08-27
CZ404997A3 (cs) 1998-06-17
US6271368B1 (en) 2001-08-07
CN1160457C (zh) 2004-08-04
AR003961A1 (es) 1998-09-30
WO1997001636A2 (de) 1997-01-16
HUP9900316A3 (en) 2002-07-29
EP0835312A2 (de) 1998-04-15
DK0751221T3 (da) 1999-06-07
MX9710522A (es) 1998-08-30
SK173197A3 (en) 1999-01-11
HU225738B1 (en) 2007-07-30
AU6416396A (en) 1997-01-30
CA2225924C (en) 2008-10-28
BR9609223A (pt) 1999-05-11
PL193281B1 (pl) 2007-01-31
EP0751221B1 (de) 1998-09-09
JPH10508206A (ja) 1998-08-18
PL324209A1 (en) 1998-05-11
JP2002300890A (ja) 2002-10-15
KR19990028570A (ko) 1999-04-15
WO1997001636A3 (de) 1997-03-27
DE59503524D1 (de) 1998-10-15
AU719297B2 (en) 2000-05-04
NO976058D0 (no) 1997-12-23
EP0751221A1 (de) 1997-01-02

Similar Documents

Publication Publication Date Title
ES2124470T3 (es) Lectina recombinante de muerdago.
RU95115239A (ru) Аналог эритропоэтина
ES2179077T3 (es) Acido glutamico decarboxilasa clonada.
PA8426301A1 (es) Bikunina humana
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
DK0559884T4 (da) Rekombinante virusvektorer til ekspression i muskelceller
ATE239789T1 (de) Chimäre prokoagulierende proteine
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
FI100056B (fi) Ihmisproapolipoproteiinin A-I ilmaiseminen
DE69833784D1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
NO960309L (no) Agonister og antagonister for humaninterleukin-10
DE69841994D1 (de) 32 Humane sekretierte Proteine
AR013529A1 (es) Rantes amino-terminalmente truncado, moleculas de adn, vector de expresion, celula huesped, proceso recombinante para prepararlo, su uso para preparar un medicamento y composicion farmaceutica que lo comprende.
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
ES2054612T3 (es) Secuencias de adn que codifican para proteinas con actividad biologica de los inhibidores husi tipo-i y procedimientos tecnologicos geneticos para la preparacion de estas proteinas.
EA200001124A1 (ru) Способ генной терапии
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
ES8606411A1 (es) Procedimiento para la determinacion de fibrina
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
FR2766190B1 (fr) Nouveaux peptides et polypeptides utiles dans la regeneration du systeme nerveux
AR029627A1 (es) Derivados de proteina c y composiciones farmaceuticas formuladas con dichos derivados, moleculas de dna recombinante que codifican dichos derivados; vectores de transformacion que comprenden dichos derivados; aislados de acidos nucleicos que comprenden polinucleotidos que codifican al menos el 90% d
DE69632963D1 (de) Mch3, eine apoptosis-protease, kodierende nukleinsäuren und methoden zur verwendung
PT714441E (pt) Alergenios recombinantes de cladosporium herbarum
EE03074B1 (et) Rekombinantsed eukarüootsed rakud, nende saamiseks vajalikud DNA järjestused, meetod eukarüootsete rakkude konstrueerimiseks ja sekreteeritavate valkude ning biomassi tootmismeetod
ITMI950442A0 (it) Frammento di dna codificante d-amminoacido ossidasi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 751221

Country of ref document: ES